Origin and prognostic value of circulating KRAS mutations in lung cancer patients

O. Gautschi, B. Huegli, A. Ziegler, M. Gugger, J. Heighway, D. Ratschiller, Philip Mack, P. H. Gumerlock, Hsing-Jien Kung, R. A. Stahel, David R Gandara, D. C. Betticher

Research output: Contribution to journalArticlepeer-review

68 Scopus citations


Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP-PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.

Original languageEnglish (US)
Pages (from-to)265-273
Number of pages9
JournalCancer Letters
Issue number2
StatePublished - Sep 8 2007


  • Circulating DNA
  • KRAS
  • Lung cancer
  • Mutation

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology


Dive into the research topics of 'Origin and prognostic value of circulating KRAS mutations in lung cancer patients'. Together they form a unique fingerprint.

Cite this